Delivery Order SPE2DB22D2211-SPE2DB25FRREV

Award Date 2/12/25
Potential Completion Date 2/13/25
Potential Value $30K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Eucrisa 2% ointment. The contract has a ceiling value of $5,787.65 and a completion date of November 29, 2023. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen has an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the procurement of Eucrisa 2% ointment. The delivery order, valued at $6,740.29, was issued under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Cencora, Inc. to provide a wide range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,913.99, is for the delivery of EUCRISA 2% Ointment 60GM, a pharmaceutical product. The contract has an ultimate completion date of September 20, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,372.25, is for the delivery of EUCRISA 2% Ointment 60GM, a pharmaceutical product. The contract is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor, and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of EUCRISA 2% ointment, a topical treatment, with a ceiling value of $5,436.23 and a period of performance through January 2, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of EUCRISA 2% ointment, a specialty pharmaceutical product, with a ceiling value of $1,554.51 and an ultimate completion date of January 14, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition....
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $2,788.14 firm fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of EUCRISA 2% ointment, a prescription medication, with a period of performance through August 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the procurement of a...
The federal contract award is for the delivery of Eucrisa 2% ointment, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,384.68 firm fixed-price delivery order was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is a part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price valued at $7,963.75, and an ultimate completion date of July 26, 2024. The award covers the procurement of EUCRISA 2% Ointment 60GM, a pharmaceutical product, to support federal healthcare programs. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of EUCRISA 2% ointment (60 gram tubes), a topical treatment for a skin condition. The contract has a ceiling value of $1,216.56 and a completion date of January 2, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRREV
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Eucrisa 2% ointment in 100 gram containers. The contract has a firm fixed price of $30,142.78 and an ultimate completion date of February 13, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/22/25, 8:27 PM